Maravai Lifesciences Holdings (MRVI) Cost of Revenue (2020 - 2026)

Maravai Lifesciences Holdings' Cost of Revenue history runs 7 years deep, the most recent figure standing at $32.1 million for Q1 2026.

• In Q1 2026, Cost of Revenue fell 17.86% year-over-year to $32.1 million; the TTM figure through Mar 2026 stood at $144.8 million (down 4.55% YoY), while the FY2025 annual figure was $151.8 million, up 0.58% from the prior year.
• Cost of Revenue was $32.1 million for Q1 2026 at Maravai Lifesciences Holdings, down from $37.0 million in the prior quarter.
• In the past five years, Cost of Revenue ranged from a high of $53.3 million in Q4 2022 to a low of $32.1 million in Q1 2026.
• Historically, Cost of Revenue has averaged $38.4 million across 5 years, with a median of $37.5 million in 2022.
• The sharpest annual moves came in 2022 and 2023: Cost of Revenue jumped 36.06% in 2022, then tumbled 34.07% in 2023.
• A 5-year view of Cost of Revenue shows it stood at $53.3 million in 2022, then plunged by 34.07% to $35.1 million in 2023, then grew by 5.87% to $37.2 million in 2024, then dropped by 0.39% to $37.0 million in 2025, then fell by 13.2% to $32.1 million in 2026.
• The last three Cost of Revenue figures came in at $32.1 million (Q1 2026), $37.0 million (Q4 2025), and $36.0 million (Q3 2025), per Business Quant data.